Setmelanotide Imcivree is a prescription medication approved for chronic weight management in patients six years of age and older with obesity caused by specific genetic mutations affecting the melanocortin system. These include POMC deficiency, PCSK1 deficiency, and leptin receptor mutations. This…
Setmelanotide, sold under the brand name Imcivree, is a medication designed to address certain rare genetic causes of severe obesity. It was the first treatment approved by the U.S. Food and Drug Administration FDA for obesity caused by specific mutations in the melanocortin system. Because these conditions are uncommon, setmelanotide is not approved for, and should not be used for, general weight management.
Melanocortin receptors are a family of proteins that respond to melanocortin peptides. The MC4 receptor is particularly important for energy balance, appetite, and body weight regulation. It is found in several brain regions, including the hypothalamus. MC3 also contributes to energy balance, while MC1 affects skin pigment production and MC5 has a less well characterized role. This background helps explain why a drug that selectively activates MC4 can be useful for certain inherited forms of obesity.
Setmelanotide is indicated for chronic weight management in patients aged six years and older with obesity caused by proopiomelanocortin POMC deficiency, proprotein convertase subtilisin/kexin type 1 PCSK1 deficiency, or mutations in the leptin receptor LEPR . POMC is a precursor protein that is cut by PCSK1 into smaller peptides, including those that activate the MC4 receptor. When POMC or PCSK1 is deficient, this activation is reduced. Leptin normally promotes POMC production, so leptin receptor mutations also disrupt the same pathway. Together, these rare conditions are sometimes described as defects in the MC4 pathway.
Chronic weight management means that the medication is used as part of a long-term treatment plan. The FDA approved setmelanotide in November 2020 as a first-in-class treatment for these specific genetic forms of obesity. The European Union approved the drug in July 2021. In Canada, setmelanotide is available as a prescription-only medicine. In all regions, the approved use is limited to patients with confirmed POMC deficiency, PCSK1 deficiency, or LEPR mutations. It is not approved for general obesity, and clinicians should confirm the genetic diagnosis before considering treatment.
Setmelanotide works as a selective agonist of the melanocortin 4 receptor. An agonist is a substance that binds to a receptor and triggers a response. By activating MC4 receptors in the paraventricular nucleus PVN and the lateral hypothalamic area LHA , the drug helps restore signaling that controls hunger and energy use. It also increases resting energy expenditure, meaning the body burns more calories while at rest. Unlike competing MC4 agonists, setmelanotide does not elevate heart rate or blood pressure, which is a notable safety advantage.
The term EC50 refers to the concentration of a drug that produces half of its maximum effect. A lower EC50 indicates higher potency at that receptor. For setmelanotide, the EC50 at MC4 is 0.27 nM, making MC4 the primary target. The drug has an EC50 of 5.3 nM at MC3, 5.8 nM at MC1, and 1600 nM at MC5. This translates to about 19.6-fold selectivity for MC4 over MC3. Selectivity matters because it can reduce unwanted effects linked to other melanocortin receptors.
The main evidence for approval came from two year-long studies. According to the reported results, most participants lost more than 10 percent of their initial body weight after one year of treatment, and several reported decreased hunger. These outcomes are consistent with the expected effect of MC4 activation on appetite. Rare disease trials commonly enroll small numbers of participants, and longer-term data are still limited.
Setmelanotide can cause injection site reactions and skin darkening. Skin darkening may be related to activation of MC1 receptors, which influence pigmentation. More serious concerns include depression and suicidal ideation, spontaneous penile erections in males, and adverse sexual reactions in females. Anyone experiencing mood changes or thoughts of self-harm should seek medical attention. Clinicians should monitor for these effects during treatment.
The compound has been known by several names during development. It was originally called BIM-22493 at Ipsen, and later RM-493. Rhythm Pharmaceuticals developed the product. The drug received orphan disease designation, breakthrough therapy status, and priority review. Orphan disease designation is for conditions affecting a small number of people, breakthrough status helps accelerate promising therapies, and priority review shortens the time the FDA spends on a submission.
As of 2021, the reported price for setmelanotide was $330 per 1 mg, a meaningful consideration for a chronic therapy. The drug was also tested in Prader-Willi syndrome, a separate genetic condition that causes obesity. Those investigations showed no demonstrated benefit. This emphasizes that setmelanotide should be reserved for conditions with a clear disruption in the MC4 pathway.
Current evidence supports the use of setmelanotide in rare genetic obesities that cause MC4 pathway disruption. It does not support use in general obesity. The data from Prader-Willi syndrome investigations are negative, so use in that condition is not supported. As with many rare disease therapies, the clinical trial population was small, and ongoing surveillance will help clarify long-term safety and effectiveness.
This educational resource is not medical advice. It discusses approved uses and known safety information for setmelanotide, as well as investigational findings in other conditions. Patients and caregivers should consult a qualified healthcare professional for guidance about genetics, testing, and treatment decisions.